393 related articles for article (PubMed ID: 28882110)
1. Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function.
Collado S; Coll E; Nicolau C; Azqueta M; Pons M; Cruzado JM; de la Torre B; Deulofeu R; Mojal S; Pascual J; Cases A
BMC Nephrol; 2017 Sep; 18(1):290. PubMed ID: 28882110
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers of vascular calcification and mortality in patients with ESRD.
Scialla JJ; Kao WH; Crainiceanu C; Sozio SM; Oberai PC; Shafi T; Coresh J; Powe NR; Plantinga LC; Jaar BG; Parekh RS
Clin J Am Soc Nephrol; 2014 Apr; 9(4):745-55. PubMed ID: 24458076
[TBL] [Abstract][Full Text] [Related]
3. Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease.
Winther S; Christensen JH; Flyvbjerg A; Schmidt EB; Jørgensen KA; Skou-Jørgensen H; Svensson M
Clin Nephrol; 2013 Sep; 80(3):161-7. PubMed ID: 23547804
[TBL] [Abstract][Full Text] [Related]
4. Brain natriuretic peptide between traditional and nontraditional risk factors in hemodialysis patients: analysis of cardiovascular mortality in a two-year follow-up.
Selim G; Stojceva-Taneva O; Spasovski G; Georgievska-Ismail L; Zafirovska-Ivanovska B; Gelev S; Dzekova P; Trajcevska L; Trojacanec-Piponska S; Sikole A
Nephron Clin Pract; 2011; 119(2):c162-70. PubMed ID: 21757955
[TBL] [Abstract][Full Text] [Related]
5. Serum osteoprotegerin is associated with vascular stiffness and the onset of new cardiovascular events in hemodialysis patients.
Lee JE; Kim HJ; Moon SJ; Nam JS; Kim JK; Kim SK; Yun GY; Ha SK; Park HC
Korean J Intern Med; 2013 Nov; 28(6):668-77. PubMed ID: 24307842
[TBL] [Abstract][Full Text] [Related]
6. Elevated Circulating Osteoprotegerin Levels in the Plasma of Hemodialyzed Patients With Severe Artery Calcification.
Krzanowski M; Krzanowska K; Dumnicka P; Gajda M; Woziwodzka K; Fedak D; Grodzicki T; Litwin JA; Sułowicz W
Ther Apher Dial; 2018 Oct; 22(5):519-529. PubMed ID: 29974642
[TBL] [Abstract][Full Text] [Related]
7. Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients.
Pateinakis P; Papagianni A; Douma S; Efstratiadis G; Memmos D
BMC Nephrol; 2013 Jun; 14():122. PubMed ID: 23758931
[TBL] [Abstract][Full Text] [Related]
8. Elevated osteoprotegerin levels predict cardiovascular events in new hemodialysis patients.
Nishiura R; Fujimoto S; Sato Y; Yamada K; Hisanaga S; Hara S; Nakao H; Kitamura K
Am J Nephrol; 2009; 29(3):257-63. PubMed ID: 18802328
[TBL] [Abstract][Full Text] [Related]
9. Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study.
Svensson M; Dahle DO; Mjøen G; Weihrauch G; Scharnagl H; Dobnig H; März W; Jardine A; Fellström B; Holdaas H
Nephrol Dial Transplant; 2012 Jun; 27(6):2571-5. PubMed ID: 22172725
[TBL] [Abstract][Full Text] [Related]
10. The ratio of osteoprotegerin to fetuin-a is independently associated with vascular stiffness in hemodialysis patients.
Kim HR; Kim SH; Han MJ; Yoon YS; Oh DJ
Nephron Clin Pract; 2013; 123(3-4):165-72. PubMed ID: 23921088
[TBL] [Abstract][Full Text] [Related]
11. Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients.
Nakashima A; Carrero JJ; Qureshi AR; Hirai T; Takasugi N; Ueno T; Taniguchi Y; Lindholm B; Yorioka N
Osteoporos Int; 2011 Jun; 22(6):1695-701. PubMed ID: 20812007
[TBL] [Abstract][Full Text] [Related]
12. Elevated osteoprotegerin is associated with inflammation, malnutrition and new onset cardiovascular events in peritoneal dialysis patients.
Koo HM; Do HM; Kim EJ; Lee MJ; Shin DH; Kim SJ; Oh HJ; Yoo DE; Kim JK; Park JT; Han SH; Kang SW; Choi KH; Yoo TH
Atherosclerosis; 2011 Dec; 219(2):925-30. PubMed ID: 22015178
[TBL] [Abstract][Full Text] [Related]
13. Fetuin A/nutritional status predicts cardiovascular outcomes and survival in hemodialysis patients.
Chen HY; Chiu YL; Hsu SP; Pai MF; Yang JY; Peng YS
Am J Nephrol; 2014; 40(3):233-41. PubMed ID: 25322785
[TBL] [Abstract][Full Text] [Related]
14. Serum osteoprotegerin is an independent marker of central arterial stiffness as assessed using carotid-femoral pulse wave velocity in hemodialysis patients: a cross sectional study.
Hou JS; Lin YL; Wang CH; Lai YH; Kuo CH; Subeq YM; Hsu BG
BMC Nephrol; 2019 May; 20(1):184. PubMed ID: 31122190
[TBL] [Abstract][Full Text] [Related]
15. Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3-5.
Marques GL; Hayashi S; Bjällmark A; Larsson M; Riella M; Olandoski M; Lindholm B; Nascimento MM
Sci Rep; 2021 Jan; 11(1):2473. PubMed ID: 33510348
[TBL] [Abstract][Full Text] [Related]
16. Serum fetuin a in hemodialysis: a link between derangement of calcium-phosphorus homeostasis and progression of atherosclerosis?
Pertosa G; Simone S; Ciccone M; Porreca S; Zaza G; Dalfino G; Memoli B; Procino A; Bonomini M; Sirolli V; Castellano G; Gesualdo L; Ktena M; Schena FP; Grandaliano G
Am J Kidney Dis; 2009 Mar; 53(3):467-74. PubMed ID: 19167798
[TBL] [Abstract][Full Text] [Related]
17. Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease.
Nascimento MM; Hayashi SY; Riella MC; Lindholm B
Braz J Med Biol Res; 2014 Nov; 47(11):995-1002. PubMed ID: 25296363
[TBL] [Abstract][Full Text] [Related]
18. Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients.
Hjelmesaeth J; Ueland T; Flyvbjerg A; Bollerslev J; Leivestad T; Jenssen T; Hansen TK; Thiel S; Sagedal S; Røislien J; Hartmann A
J Am Soc Nephrol; 2006 Jun; 17(6):1746-54. PubMed ID: 16687626
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure.
Kuźniewski M; Fedak D; Dumnicka P; Stępień E; Kuśnierz-Cabala B; Cwynar M; Sułowicz W
Adv Med Sci; 2016 Sep; 61(2):269-275. PubMed ID: 27128817
[TBL] [Abstract][Full Text] [Related]
20. Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease.
Matsubara K; Stenvinkel P; Qureshi AR; Carrero JJ; Axelsson J; Heimbürger O; Bárány P; Alvestrand A; Lindholm B; Suliman ME
J Nephrol; 2009; 22(6):774-82. PubMed ID: 19967657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
